Searched for
THERAPY DRUGS CHINA
Why CDSCO and BEE have not kept pace with the industries they overseeCDSCO still faces challenges like chronic understaffing, gaps in technical skills, weak lab infra and fragmented approvals. About a decade ...- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsFrom a macro perspective, it is clearly a good time to be bullish. But as valuations remain high in parts of the market despite the recent ...
- Indian pharma leaving generics era behind, but the Street hasn't caught up yet: Nandan KulkarniIndian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...
- India needs to remain attractive for innovation-led investment: Judith Love, NovartisWith an eye on India's blossoming market, Novartis is set to launch pioneering therapies, including radioligand and gene therapies. The com...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight lossAlkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordabl...
- FDA approval puts Wockhardt’s Zaynich in $9 billion antibiotics marketWockhardt's new antibiotic, Zaynich, has received US FDA approval. This drug uses a novel mechanism to fight drug-resistant bacteria. It ta...
- GSK's chronic hepatitis B drug helps one in five achieve functional cure in key studiesGSK's experimental hepatitis B drug, bepirovirsen, showed promising results in late-stage studies, with nearly one in five patients achievi...
- Top cases on the United States Supreme Court's docketThe U.S. Supreme Court is reviewing significant cases. These cases cover voting rights, presidential authority, immigration policies, and g...
- From oncology to obesity, Pfizer bets big on India for its next growth wavePfizer is prioritizing India for future growth. The company plans to launch new medicines here soon after their global release. Pfizer aims...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Sun Pharma to acquire Organon for $11.75 billion in India’s biggest pharma dealSun Pharma, led by Dilip Shanghvi, has agreed to acquire US-based Organon in an all-cash deal worth $11.75 billion, marking the largest acq...
- Obesity drug market to gain as Indians pop the pill and Chinese bring moreIndia's obesity treatment market is set for a major shift by year-end. A wave of oral GLP1 weight-loss pills, including those from China, w...
- Semaglutide API price plunges amid GLP-1 rushGlobal demand for weight-loss drugs Ozempic and Wegovy has caused semaglutide prices to drop significantly. Manufacturing has expanded rapi...
- China pulls ahead in biologics race, forcing Indian drugmakers to rethink strategyIndia's drug companies face a tough race in the global biologics market. China is quickly becoming a leader in biotech supply chains. India...
- Biocon urges government to exempt cancer, rare-disease drugs from tax in budgetIndia should eliminate tax on drugs for cancer treatment and chronic diseases, urged Biocon's chairperson Kiran Mazumdar-Shaw, ahead of the...
- PLI scheme for pharma to benefit 55 firms, says CentreThe first category included biopharmaceuticals, complex generic drugs, patented drugs or drugs nearing patent expiry, cell-based or gene th...
- In search for a cure, government set to start blood plasma trialsMove comes after Kerala used this approach. ICMR may release protocol in a couple of days. The convalescent plasma therapy works on the sci...
- Coronavirus: Health research body may suggest alternative medicinesA government-led expert panel has asked India’s top health research body to recommend alternative medicines or therapies for some antibioti...
- Chronic illness sees a spurt in business opportunity for pharma marketAccording to data from AIOCD, the Indian pharma market has grown at a compound annual growth rate of 3.3% in volume terms in the past five ...
Load More
